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White matter hyperintensities (WMH) are regions of increased signal on T2-weighted magnetic resonance imaging (MRI) sequences of the brain. 1 The extent of WMH has been correlated with mild cognitive impairment (MCI) 2, 3 , dementia 4, 5 , as well as cortical atrophy 6 .
Besides, WMH may contribute to the progression from MCI to dementia. 5, 7 The severity of WMH increased among patients diagnosed as clinical or preclinical Alzheimer's disease (AD), 1, 8 which reliably predicts who are at risk of developing AD, 9 and predicts rate of cognitive decline among AD individuals. 10 As for the interaction between WMH and AD pathology, WMH may not only be an independent process causing dementia in combination with coexisting yet unrelated AD pathology, but also lead directly to AD pathology by increasing amyloid accumulation rates due to ischemic disorders or by inducing ischemia because of amyloid accumulation in the vessels (cerebral amyloid angiopathy). [11] [12] [13] [14] These lines of evidence together indicated that WMH might be involved in the pathogenesis of cognitive disorders and be promising in monitoring cognitive progression at early stage, and assessing treatment efficacy in clinical practice or drug trials.
Although previous articles have uncovered some loci that affect WMH volume (WMHV), the associations of these genetic modulators with disease risk remain poorly understood. A recent meta-analysis revealed that PLEKHG1 was linked to WMHV and ischemic stroke, motivating further identification of WMHV-associated loci. 15 The application of quantitative phenotypes in genome-wide association studies (GWAS) shed light on associations between genes and their correlated pathways. 16 Moreover, MRI measurements have great strengths in monitoring changes in brain structure and function, such as adequate sensitivity, non-invasiveness, ease of access, and good tolerance. 17 And WMHV can be reliably measured in vivo. Herein, we performed a GWAS using WMHV as an endophenotype to explore genetic predictors associated with WMHV in non-demented elders. These genetic factors may be involved in cognition-related pathophysiological processes.
METHODS

Alzheimer's Disease Neuroimaging Initiative (ADNI)
ADNI, a large, multicenter, longitudinal neuroimaging study, was initiated in 2003 by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private pharmaceutical companies, and non-profit organizations. 18 ADNI was established to explore the effectiveness of integrating neuroimaging, genetic/biological markers, as well as clinical and neuropsychological assessments in measuring the early diagnosis and progression of AD. Regional ethical committees of all institutions approved the ADNI study.
Written informed consent was obtained from all participants or authorized representatives.
Participants
Data used in preparation for this study were derived from the ADNI database (http://adni.loni.usc.edu/). Baseline and longitudinal clinical and neuropsychological test results, neuroimaging scan information, and data about clinical diagnosis from all participants were available. Detailed procedures for sample screening were presented in appendix 1. The full cohort with both GWAS and WMHV data comprised 425 subjects aged 55 to 80 years. To reduce the likelihood of population stratification effects in the GWAS, all samples were restricted to non-Hispanic Caucasians (n = 385). To avoid the influence of dementia on results, only non-demented individuals at baseline (n = 355) were included in this study. To test cryptically related subjects and/or sample mix-ups, genomic identify-by-descent and multidimensional scaling (MDS) components were performed using PLINK. 19 This step excluded 3 subjects who 6 showed cryptically associated and clustering separately from the other participants (appendix 2), leaving 352 valid samples. Finally, all samples presented close clustering with individuals of European descent using the HapMap cohort.
WMHV and QC
WMH regions were segmented via a multimodal segmentation method, white matter lesion segmentation (WMLS), using T1-weighted and fluid-attenuated inversion recovery (FLAIR) images. 20 FLAIR MRI was corrected for inhomogeneity and warped to T1 images to provide the segmentation. WMHs are seeded at points that are > 3.5 standard deviations (SD) from the mean signal in white matter, and final segmentation is based on a Bayesian approach, combining spatial priors and tissue class constraints. The WMH segmentation also comprised segmentations of white matter, gray matter, and cerebrospinal fluid (CSF); the sum of the tissue volumes was applied as a surrogate of intracranial volume (ICV). For analysis, WMHV values were log transformed to achieve a normal distribution because the values were skewed (Shapiro-Wilk test P < 0.05). Log (WMHV) was then used as a quantitative outcome phenotype for the GWAS. QC was conducted to mitigate the influence of extreme values on statistical results. Mean and SD of baseline WMHV measures were calculated by observers blinded to clinical data, and the figures greater or smaller than 5.5-fold SD from the mean value were considered as extreme outliers and were excluded from this analysis. After removal of 2 outliers, there were 350 valid samples left.
Vascular information, neuroimaging, and cognition
The baseline vascular information, including history of heart disease and hypertension, were accessed by screening the medical information database. Body mass index (BMI) was utilized to determine obese conditions following the world health organization criteria: overweight/obese ≥ 7 25 kg/m 2 , normal weight < 25 kg/m 2 . Structural brain MRI was acquired using a Siemens Trio 3.0T scanner or Vision 1.5T scanner.
Regional volume estimates were processed using Free-surfer software package version 4.3 and 5.1 image processing framework for the 1.5T and 3.0T MRI images, respectively. Regions of interests (ROIs) included the hippocampus and entorhinal cortex. 
Genotyping and QC
All samples were genotyped using the Illumina Human Hap610-Quad BeadChips featuring 2,379,855 single nucleotide polymorphisms (SNPs). Prior to association analysis, all samples and genotypes underwent stringent QC with the following criteria: call rates for SNPs > 98%, call rates for individuals > 95%, minor allele frequencies (MAF) > 0.20 and Hardy-Weinberg equilibrium test P > 0.001. We set the MAF value > 0.20 for SNPs to improve statistical power and reduce potentially false-positive results in the context of modest sample size. Finally, the filters based on QC produced a total of 695,203 imputed and genotyped SNPs for analyses. The overall genotyping rate for the remaining dataset was 99.7%.
Statistical analyses
Mann-Whitney U test was used to determine the difference in baseline WMHV measures of different diagnostic groups. We performed a GWAS of WMHV with genetic polymorphisms, using multiple linear regression under an additive genetic model in PLINK v1.9 software.
Principle component analysis was performed in PLINK and the first three MDS components were applied as covariates in the GWAS. Age at baseline, gender, dosage of APOE ε4 allele, baseline diagnosis and ICV were also used as covariates. To account for multiple comparisons, we set the thresholds for genome-wide significant and suggestive associations at P < 5 × 10 -8 and P < 1 × 10 -5 , respectively. 21 Genome-wide associations were visualized using R package "qqman" and regional association plots were generated with the LocusZoom web tool (http://locuszoom.org/). Age, gender, dosage of APOE ε4 allele, baseline diagnosis and ICV were applied as covariates.
Bioinformatics analyses
SNP annotations were conducted via the NCBI Database of SNPs 
RESULTS
Characteristics of included subjects
Demographic characteristics of the study population are listed in Table 1 and appendix 3.
Briefly, 240 MCI (105 women, 69.6 ± 5.9 years) and 110 HC (62 women, 72.2 ± 4.1 years) subjects were enrolled from the ADNI cohort. Linear correlations between age at baseline and log (WMHV) were found in both HC (P = 0.0374) and MCI (P < 0.0001) groups (appendix 4).
However, there was no significant difference in WMHV between males and females (MCI P = 0.105, HC P = 0.974, Total P = 0.153) among the diagnostic groups (appendix 5). MCI group (45.4%) had a higher frequency of ε4 allele within APOE gene than HC group (29.1%) (P = 0.004). MCI group also had higher baseline WMHV compared to HC group (P < 0.001) (appendix 6).
SNPs associated with WMHV
A total of 350 subjects were identified for GWAS. After adjustment for age, gender, dosage of APOE ε4 allele, baseline diagnosis, ICV and the first three MDS components, a genome-wide significant association of rs7220676 (near HS3ST3A1 and MIR548H3 gene, P = 2.96 × 10 -8 ) with
WMHV was detected ( Figure 1A) . SNPs mapped closely to the top SNP (rs7220676) region were also analyzed ( Figure 1B) .
These nearby SNPs showed associations with WMHV levels at P < 0.01. After controlling for genotypes of rs7220676, the association signals for these nearby SNPs were dramatically attenuated ( Figure 1C ). The Quantile-Quantile plot didn't show evidence of spurious inflation in test statistics (the genomic inflation factor = 1) due to population stratification or other confounders (appendix 8).
Four SNPs met criteria for suggestive levels of genome-wide significance (P < 1 × 10 -5 ) ( , and the minor allele of rs10916409 (C) (P = 1.56 × 10 -5 ) were associated with lower log-WMHV measures in a dose-dependent manner among the whole samples, whereas the minor allele of rs540422 (T) (P = 3.01 × 10 -5 ) was associated with higher log-WMHV measures in a dose-dependent manner (appendix 9). Figure 3B ), whereas no other significant associations of rs9675262 genotypes were revealed with other phenotypes of interest in HC and MCI groups.
Impact of the top SNPs on cognitive scores and brain structures
Bioinformatics analyses
As for eQTL analyses, the minor allele of rs9820240 (A) (P = 0.0055) and the minor allele of rs540422 (T) (P = 0.04) were downregulated in putamen and frontal cortex, respectively. Besides, 12 rs540422 has a cis-eQTL effect on PICALM (Z = -4.57, P = 4.83 × 10 -6 ) in whole blood (appendix 10). 22
DISCUSSION
This study conducted a GWAS of WMHV in non-demented elders. We identified genome-wide significant associations of a novel SNP (rs7220676) near HS3ST3A1 and MIR548H3 HS3ST3A1 gene has been reported to be involved in human immunodeficiency virus (HIV) infection 23 , Plasmodium falciparum parasitaemia 24, 25 , lung cancer 26 , and respiratory papillomatosis 27 . However, no research has explored the relationships between HS3ST3A1 gene and cognitive disorders. MIR548H3 gene is a member of micro Ribonucleic Acid (microRNA) family, which participates in the post-transcriptional modulation of gene expression in multicellular organisms through influencing the stability and translation of messenger Ribonucleic Acids (mRNAs). 28 Accumulating evidence showed that microRNAs might play an important role in the development of central nervous system and neuropsychiatric diseases, 29, 30 and the potential 13 associations of MIR548H3 gene with neuroticism 30 , epilepsy and mild intellectual disability 31 have been discussed in previous studies. At present, the specific mechanisms through which MIR548H3 regulates cognition-related diseases remain poorly understood. There are several fundamental issues that need to be addressed, for example, whether microRNAs are particularly important in specific neurodegenerative diseases and which microRNA targets are linked to the disease, etc. Collectively, there is still a long way to go for research on the mechanism between the novel loci and cognitive function.
There was a suggestive SNP in the PICALM gene. The involvement of this gene in cognitive impairment has been highlighted. As one of the most highly validated AD risk factors, PICALM
can be expressed in all tissues, and it shows prominent expression in neurons, where it is non-selectively distributed in the pre-and postsynaptic structures. 32 Mutations in PICALM can cause synaptic perturbations, possibly through synaptic vesicle cycling, thus increasing the risk of AD. Alternatively, PICALM may influence AD risk through amyloid precursor protein (APP) trafficking via endocytic pathways, causing changes in amyloid beta (Aβ) levels. 32 This evidence also got support from the biological aspect. One experiment in yeast, nematodes, and rat cortical neurons confirmed the role of PICALM in suppressing the toxicity of soluble Aβ oligomers and linking Aβ to the genetics of AD. 33 Moreover, the impact of PICALM on disproportionate frontal damage, executive dysfunction 34 , hippocampal degeneration 35 , Pick disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and frontotemporal lobar degeneration (FTLD) 36 provided further evidence support. However, the regions on chromosome 3 (DCLK3) and 1 (ISCA1P2) associated with WMHV have not been previously shown to have correlations with cognitive disorders. DCLK3 can modulate the expression of many genes participating in transcriptional regulation and nucleosome/chromatin remodeling in a kinase-dependent way. The kinase that DCLK3 expressed is preferentially distributed in neurons of the striatum and dentate gyrus, and DCLK3 may produce neuroprotection against Huntington's disease. 37 Also, DCLK3 may promote colorectal cancer progression, 38 and involve in the development of glaucoma. 39 But the function of ISCA1P2 has never been investigated. Further studies are especially warranted to explore how DCLK3 and ISCA1P2 genes mediate the progression of cognitive diseases.
Compared with previous articles similar to our topic, [40] [41] [42] [43] this study was conducted in a different population and has found novel loci associated with WMHV in non-demented elders.
Although some suggestive SNPs didn't reach the genome-wide significance level, they may have the potential significance in other studies with sample enrichment. When controlling for rs7220676 genotypes, the nearby association signals diminished, which indicated that the associations in nearby loci might be driven by rs7220676. Besides, the associations of rs7220676 genotypes with WMHV were not significant among the population with heart disease or normal BMI, which may be due to the insufficient sample. Given that the relationship between rs7220676
and vascular factors has never been reported, it's difficult to explain the specific mechanisms.
After the GWAS scan, we assessed associations of rs7220676 with other cognition-related endophenotypes. Interestingly, the minor allele of rs7220676 (C) was associated with change rate of MEM score in HC population rather than in MCI patients. It could thus reasonably be implied that the modifying effects of rs7220676 might be more evident in subjects with normal cognition.
Our research suggested that rs7220676 might be associated with cognitive disease among non-demented elders, and further studies are needed to confirm this.
Some limitations must be acknowledged. Firstly, the sample size for analysis was relatively small especially in subgroup analyses, leading to limited ability to identify variants with small effects. Secondly, only non-Hispanic Caucasians were included to avoid population stratification across ethnicities, which limited the generalizability of this study. Thirdly, we applied a stringent In conclusion, we identified novel genome-wide significant associations of a SNP (rs7220676) near HS3ST3A1 and MIR548H3 genes and 4 additional suggestive association loci (in DCLK3, PICALM genes, near ISCA1P2, HS3ST3A1 and MIR548H3 genes) with baseline WMHV levels.
The mechanisms underlying the associations between these novel genetic loci and cognitive disorders are worth exploring. Besides, further validation of these novel genetic associations in large samples and different populations is warranted. 
